Mairi McClean

Mairi McClean

Auto-generated profile, based on publicly available information

Mairi McClean

Institute of Infectious Diseases and Tropical Medicine, LMU University Hospital Munich Germany

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2024 in Breathe
Verified
Journal Article
Open access
PDF file
MMMairi McClean
Mairi McClean
TPTraian-Constantin Constantin Panciu
Traian-Constantin Constantin Panciu
CLChristoph Lange
Christoph Lange
RDRaquel Duarte
Raquel Duarte
FTFabian Theis
Fabian Theis
The challenges to effective tuberculosis (TB) disease control are considerable, and the current global targets for reductions in disease burden seem unattainable. The combination of complex pathophysiology and technical limitations results in difficulties in achieving consistent, reliable diagnoses, and long treatment regimens imply serious physiological and socioeconomic consequences for patients. Artificial intelligence (AI) applications in healthcare have significantly improved patient care regarding diagnostics, treatment and basic research. However, their success relies on infrastructures prioritising comprehensive data generation and collaborative research environments to foster stakeholder engagement. This viewpoint article briefly outlines the current and potential applications of advanced AI models in global TB control and the considerations and implications of adopting these tools within the public health community.

21 January 2026 in medRxiv
Verified
Preprint
Open access
PDF file
MMMairi CW McClean
Mairi CW McClean
SKSimon E Koele
Simon E Koele
JDJulia Dreisbach
Julia Dreisbach
SMSusanne Mirold-Mei
Susanne Mirold-Mei
FNFred Njeleka
Fred Njeleka
MHMichael Hoelscher
Michael Hoelscher
Culture-based monitoring of bacterial load is slow and susceptible to missing data, contributing to the length and cost of TB clinical trials. Non-culture-based alternatives, like the Tuberculosis Molecular Load Bacterial Assay (TB-MBLA), could represent a solution. Our objectives were to evaluate TB-MBLA as a biomarker in early bactericidal activity (EBA) studies and explore whether combining biomarkers with joint modelling could provide insight into underlying biological processes and reduce data loss. We generated TB-MBLA (LifeArc (R) ) data from sputum samples from all 78 patients from the PanACEA BTZ-043 Phase Ib/IIa trial. In addition, we defined a joint biomarker as the first principal component derived from a probabilistic principal component analysis (pPCA) integrating TB-MBLA, colony forming units (CFU), and time-to-positivity (TTP) data. With TB-MBLA alone and the principal component 1 (PC1) marker we reevaluated the original stage IIa dose-response and stages Ib/IIa pharmacokinetics - pharmacodynamics (PK-PD) exposure-response analyses, applying linear and non-linear mixed models, respectively. For TB-MBLA, we could not detect an exposure-response effect in the PK-PD analysis, in contrast with CFU and TTP. When combining biomarkers, we observed a significant but less pronounced Emax exposure–response between days 0–3 compared with CFU and TTP alone. We also successfully applied pPCA as a modelling framework and show evidence that combining CFU and TTP in a joint latent component can improve detection of treatment effects compared with either biomarker alone. STUDY HIGHLIGHTS: What is the current knowledge on the topic?: BTZ-043 is a first-in-class antimycobacterial compound with promising applications in drug-sensitive pulmonary tuberculosis. TB EBA trials are typically conducted using sputum culture assays for dose-exposure-response modelling, but the technical challenges of these assays limit their effectiveness. What question did this study address?: How does the novel RT-qPCR assay TB-MBLA perform as a dose-exposure response marker for novel antitubercular compound BTZ-043 and what are the effects of joint modelling approaches in EBA modelling tasks? What does this study add to our knowledge?: We did not observe a significant exposure response for BTZ-043 in TB-MBLA over the 14-day treatment window. Joint modelling with pPCA can overcome the issues of missing and contaminated data that are canonical of culture data from TB treatment monitoring cohorts. How might this change drug discovery, development, and/or therapeutics?: Designing EBA trials should consider the drug-bacterial subpopulation axis of the specific study drug to maximise efficiency. Latent variable modelling techniques can be an effective and efficient framework for modelling Mycobacterial tuberculosis load in EBA trials.

19 April 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
MMMairi McClean
Mairi McClean
OBOlga Baranov
Olga Baranov
MAMohamed I.M. Ahmed
Mohamed I.M. Ahmed
NBNadja Bräuer
Nadja Bräuer
INIvan Noreña
Ivan Noreña
KHKathrin Held
Kathrin Held
Background: Tuberculosis (TB) disease recurrence contributes significantly to the global disease burden and substantially increases the duration and cost of clinical trials evaluating novel TB regimens, thereby delaying the development and deployment of urgently needed improved TB treatments. Despite this, there are currently no clinically validated biomarkers capable of identifying persons at risk of recurrence.Methods: We conducted a multi-country validation of published transcriptomic signatures for predicting TB disease recurrence in participants enrolled in a clinical trial. We also performed longitudinal modelling of paired clinical covariates to describe the differences in outcome-specific trajectories between groups in easily measurable clinical covariates. We also conducted exploratory multivariate logistic regression with leave-one-out cross-validation to compare performance of different feature combinations for long-term outcome prediction. To the best of our knowledge, this study represents the first multi-country validation of transcriptomic signatures for the prediction of TB recurrence in a clinical treatment trial setting.Findings: Both host transcriptomic and clinical biomarkers contain predictive signal for recurrence, and we identified candidate transcriptomic signatures that meet WHO Target Product Profile criteria for on-treatment monitoring tests. At week 26, Sweeney-3 showed highest performance [area under the receiver operating characteristic curve= 0.87 (0.68-1)]. We also observed outcome group-specific changes in BMI and heart rate over time. Combining transcriptomic and covariates did not result in appreciable gain in performance.Interpretation: These results highlight the potential of host-response biomarkers to support non-culture-based prediction of treatment outcomes and may help inform the development of risk-stratified treatment monitoring strategies. Validation in larger cohorts are required to fully determine the performance of multivariate modelling.

7 August 2026 in CPT: Pharmacometrics & Systems Pharmacology
Verified
Journal Article
Open access
MMMairi C. W. McClean
Mairi C. W. McClean
SKSimon E. Koele
Simon E. Koele
JDJulia Dreisbach
Julia Dreisbach
SMSusanne Mirold‐Mei
Susanne Mirold‐Mei
FNFred Njeleka
Fred Njeleka
MHMichael Hoelscher
Michael Hoelscher
Culture‐based monitoring of bacterial load is slow and susceptible to missing data, contributing to the length and cost of TB clinical trials. Non‐culture‐based alternatives, like the Tuberculosis Molecular Load Bacterial Assay (TB‐MBLA), could represent a solution. Our objectives were to evaluate TB‐MBLA as a biomarker in early bactericidal activity (EBA) studies and explore whether combining biomarkers with joint modeling could provide insight into underlying biological processes. We generated TB‐MBLA (LifeArc) data from sputum samples from all 78 patients from the PanACEA BTZ‐043 Phase Ib/IIa trial and derived a summary measure of the joint distribution of the three TB‐MBLA, colony forming units (CFU), and time‐to‐positivity (TTP) biomarkers as the first principal component derived from a probabilistic principal component analysis (pPCA). With TB‐MBLA marker and the principal component 1 (PC1) values, we reevaluated the original stage IIa dose–response and stages Ib/IIa pharmacokinetics—pharmacodynamics (PK‐PD) exposure‐response analyses, applying linear and non‐linear mixed models, respectively. For TB‐MBLA, we could not detect an exposure‐response effect in the PK‐PD analysis, in contrast with CFU and TTP. When combining biomarkers, we observed a significant but less pronounced E max exposure–response between days 0–3 compared with CFU and TTP alone. We also successfully applied pPCA as a modeling framework and show evidence that combining CFU and TTP in a joint latent component can improve detection of treatment effects compared with either biomarker alone. In this study, we present novel EBA data for the first‐in‐class antimycobacterial compound BTZ‐043 and contextualize the value of emerging bacteriological markers within the EBA trial framework. Trial Registration: ClinicalTrials.gov identifier: NCT04044001

29 July 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
MMMairi McClean
Mairi McClean
LLLeyla Larsson
Leyla Larsson
ARAlia Razid
Alia Razid
CNCong Minh Nguyen
Cong Minh Nguyen
CWCarla Winston
Carla Winston
JEJuan Espinosa-Pereiro
Juan Espinosa-Pereiro
Background: Treatment response biomarkers that rapidly identify and prioritize effective interventions are urgently needed to improve treatment for people with tuberculosis (TB). However, trial efficacy is limited by culture-based outcome monitoring, which is unreliable and technically demanding. Recent publication of the World Health Organisation (WHO) Target Product Profiles (TPPs) offers an interpretable consensus benchmark for which to evaluate novel biomarkers for treatment response. Objectives: We sought to conduct an update to our previous review to evaluate all newly published TB treatment biomarkers and evaluate their performance against WHO TPP standards. Methods: The protocol was registered with PROSPERO (CRD 42021225507). We searched PubMed, Embase and Cochrane databases for studies including participants ≥15 years old with confirmed pulmonary TB with culture as a reference, regardless of current or previous TB treatment and resistance profile. We excluded all studies not reported in English, Portuguese, German or French, studies in patients with extrapulmonary TB, and conference abstracts and proceedings. We performed a risk of bias assessment using the QUADAS-2 tool. We extracted performance data including sensitivity, specificity, area under the receiver-operator curve (AUC), and correlation measures (Rho). We grouped biomarkers to align with the culture-based endpoints used in phase 2 and 3 TB clinical trials: α, bacterial load estimates; β, interim study endpoints; γ, on-treatment markers for long-term outcome; and δ, baseline risk stratification markers for long-term outcome prediction. We then compared them to the WHO TPP thresholds for a baseline or on-treatment marker for long-term outcome. Results: From 30 studies involving 4391 patients, we extracted 656 novel biomarker entries. From these, we extracted complete data from 385 that were reported with at least one relevant performance metric. We categorised each into α (n=45), β (n=90), γ (n= 165) or δ (n=85) groups, and found 21 entries that reached the minimum WHO TPP thresholds, including one for TB disease recurrence. Despite these encouraging results, the biomarker research field would be better equipped with access to guidance on conduct of biomarker research, including data analysis and reporting.